\n<\/p>\n
Conno Christou doesn\u2019t leave things to chance. He tracks his sleep with a Whoop band, cross-references it with an Oura ring, and gets nearly 100 biomarkers checked every year. He had been doing the annual bloodwork for four consecutive years, following the protocols of longevity researchers like Peter Attia and Rhonda Patrick. He was optimizing his supplements, his circadian rhythm, his protein intake. <\/p>\n
At 35, building his second company, he was as dialed-in on the latest in health research as anyone he knew. His last checkup, in 2025, was green across the board. \u201cIt was the best I\u2019d had in years,\u201d he says.<\/p>\n
Then, after a workout, his arm swelled.<\/p>\n
He didn\u2019t think much of it at first. A week passed before he saw a doctor, who found two blood clots in his veins and scheduled surgery. But the pre-op exams changed everything. A doctor walked back into the room and told him the procedure wasn\u2019t happening.<\/p>\n
\u201cWe see an 11-by-11-by-8 centimeter mass behind your sternum,\u201d the doctor said.<\/p>\n
A biopsy confirmed what Christou had never before even contemplated. He had an aggressive, fast-growing form of non-Hodgkin\u2019s lymphoma \u2014 a rare diagnosis affecting roughly one in 420,000 people, caused by a random genetic mutation with no connection to lifestyle, diet, or stress. <\/p>\n
The tumor had only existed for about three months. In three more weeks, it would have reached stage four.<\/p>\n
\u201cLucky in my unluckiness,\u201d Christou told this editor this week from his home in Athens, where he lives part time. \u201cIt was only found because I went in for something else entirely.\u201d<\/p>\n
What followed was an education in the limits of the medical system, and in what a determined patient can do about that with tools now available.<\/p>\n
His first oncologist, a renowned specialist, recommended the lighter of two available chemotherapy regimens. Christou booked his first infusion three days out. Then, the night before, he sought a second opinion.<\/p>\n
That doctor didn\u2019t hesitate. He recommended the harder regimen \u2014 continuous in-hospital infusion, cycling every three weeks across six months \u2014 citing Christou\u2019s specific pathology. The lighter treatment carried roughly a 60% success rate for his presentation. The aggressive one brought that number to around 85%. Two world-class doctors. Diametrically opposite recommendations.<\/p>\n
\u201cAs founders, we hold the wheel,\u201d Christou says of the propensity of many people to accept what they are told \u2014 and why more should not. \u201cYou hear many things. You don\u2019t have to follow the first advice.\u201d<\/p>\n
He didn\u2019t opt to just follow the second advice, either. Over the next two days, he gathered 12 opinions in total \u2014 drawing on his professional network, reaching out to hematologists and oncologists in the US and abroad, calling in every favor he could. Eleven to one voted in favor of the harder path. He took it. The decision, he says, didn\u2019t feel brave so much as logical. When the stakes are existential, you collect data.<\/p>\n
Over six months of treatment, Christou approached chemotherapy the way he approached building a company: as a marathon of sprints, each of them with a finite cycle, each week filled with data points. He had done a mandatory 25-month military service in Cyprus at age 18 and he borrowed from that experience, too. He was going to be a good soldier, he told himself. Trust the process. Six cycles. Get through it.<\/p>\n
He wore his Whoop throughout, and found it remarkably accurate at predicting the days his immune system would bottom out, sometimes flagging them before symptoms arrived. He kept a symptom journal using voice transcription, logging every shift, every side effect, every medication and counter-medication. He narrowed his focus to three variables: sleep, nutrition, and, first and foremost, psychology. (\u201cIt moves the needle more than anything,\u201d said Christou. \u201cI never asked \u2018why me\u2019 \u2014 not once. That question has no useful answer.\u201d)<\/p>\n
He fed all of it \u2014 blood results, scan data, wearable output, journal entries \u2014 into Claude. He\u2019s far form alone in turning to chatbots for medical guidance. A public opinion poll<\/a> released in March found that a third of American adults now use them for health information and advice. The stories<\/a> accumulating online suggest that for some patients, AI is delivering what the system couldn\u2019t. <\/p>\n Experts urge caution; Danielle Bitterman, clinical lead for data science and AI at Mass General Brigham, has told the New York Times in recent months that general-purpose chatbots are frequently wrong<\/a> and \u201chave not been thoroughly evaluated\u201d for personalized diagnoses. <\/p>\n Christou doesn\u2019t disagree. \u201cIt didn\u2019t replace the doctors,\u201d he says, but it \u201chelped me ask the right questions.\u201d <\/p>\n For a condition as rare as his \u2014 one an oncologist might see once a year \u2014 access to a model that had absorbed the full body of medical literature was, he says, simply not the same as a Google search.<\/p>\n That distinction proved critical at the end of treatment. His final PET scan \u2014 the imaging used to detect active disease \u2014 came back ambiguous. His oncologist began discussing a second line of therapy, potentially radiotherapy, near his heart and lungs. It was an alarming development.<\/p>\n Christou again did his homework. He read that for this specific lymphoma, the false-positive rate on end-of-treatment PET scans is around 60% \u2014 a statistic that still astonishes him. \u201cIt\u2019s 2026,\u201d he says. \u201cSixty percent.\u201d <\/p>\n He fed all three of his PET scans and his MRI into Claude, which flagged a known but easily overlooked phenomenon: in patients under 40 recovering from this type of lymphoma, the thymus gland can reactivate after chemotherapy, showing up on imaging as what appears to be active disease. Given his age, his specific scan characteristics, the model put the probability of that explanation at roughly 90%.<\/p>\n He sought three more opinions. The fourth doctor confirmed it: thymus rebound. There was no active disease. No radiotherapy was needed. He was clear.<\/p>\n Christou is still unfolding what the last year has meant, for his health, how he works, and how he thinks about time. He built Keragon, his current company, before any of this happened; it\u2019s an AI-powered platform that helps medical practices automate their administrative operations. <\/p>\n But going through the system as a patient has given him new perspective. He watched nurses and doctors buried under tasks that had nothing to do with care. He received the same chemotherapy protocol as an 80-year-old woman, the side effects managed through a cascading chain of additional drugs, each causing problems of their own. He says he\u2019s certain that we will look back at this era of treatment and cringe.<\/p>\n He takes Sundays off now, mostly. He tries to be present \u2014 at lunch with friends, at home with his dog, in conversations that might once have felt like a distraction from work. A VC friend told him something years ago that he said he kept replaying during treatment: Be happy now. He says it\u2019s among the hardest things to do and yet he finally appreciates its importance.<\/p>\n He says he\u2019d be happy to talk to anyone going through something similar to share notes, compare experiences. He seems to means it.<\/p>\n \u201cIt\u2019s not happening in 10 years,\u201d he says of what AI can already do for patients willing to use it. \u201cIt\u2019s happening today.\u201d<\/p>\n<\/div>\n When you purchase through links in our articles, we may earn a small commission<\/a>. This doesn\u2019t affect our editorial independence.<\/em><\/p>\n